CN101611048B - 含有高浓度鸟嘌呤单体的寡核苷酸 - Google Patents

含有高浓度鸟嘌呤单体的寡核苷酸 Download PDF

Info

Publication number
CN101611048B
CN101611048B CN2007800498509A CN200780049850A CN101611048B CN 101611048 B CN101611048 B CN 101611048B CN 2007800498509 A CN2007800498509 A CN 2007800498509A CN 200780049850 A CN200780049850 A CN 200780049850A CN 101611048 B CN101611048 B CN 101611048B
Authority
CN
China
Prior art keywords
oligonucleotide
solvent
seq
coupling
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800498509A
Other languages
English (en)
Chinese (zh)
Other versions
CN101611048A (zh
Inventor
B·S·斯普罗特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuros Biosciences
Kuros US LLC
Original Assignee
Cytos Biotechnology AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology AG filed Critical Cytos Biotechnology AG
Publication of CN101611048A publication Critical patent/CN101611048A/zh
Application granted granted Critical
Publication of CN101611048B publication Critical patent/CN101611048B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800498509A 2006-12-12 2007-12-12 含有高浓度鸟嘌呤单体的寡核苷酸 Active CN101611048B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86958806P 2006-12-12 2006-12-12
US60/869,588 2006-12-12
PCT/US2007/087183 WO2008073960A2 (en) 2006-12-12 2007-12-12 Oligonucleotides containing high concentrations of guanine monomers

Publications (2)

Publication Number Publication Date
CN101611048A CN101611048A (zh) 2009-12-23
CN101611048B true CN101611048B (zh) 2012-11-07

Family

ID=39456527

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800498509A Active CN101611048B (zh) 2006-12-12 2007-12-12 含有高浓度鸟嘌呤单体的寡核苷酸

Country Status (7)

Country Link
US (3) US8586728B2 (https=)
EP (1) EP2125854B1 (https=)
JP (1) JP5389662B2 (https=)
CN (1) CN101611048B (https=)
AU (1) AU2007333147B2 (https=)
CA (1) CA2671873C (https=)
WO (1) WO2008073960A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008063490B4 (de) * 2008-12-17 2023-06-15 Merck Patent Gmbh Organische Elektrolumineszenzvorrichtung und Verfahren zum Einstellen des Farbortes einer weiß emittierenden Elektrolumineszenzvorrichtung
WO2012059510A1 (en) 2010-11-02 2012-05-10 Girindus America, Inc. Back pressure control during solid-phase synthesis on polymeric supports
US10040048B1 (en) 2014-09-25 2018-08-07 Synthego Corporation Automated modular system and method for production of biopolymers
DK3240801T3 (da) 2014-12-31 2021-02-08 Checkmate Pharmaceuticals Inc Kombinationstumorimmunterapi
WO2017005818A1 (en) * 2015-07-08 2017-01-12 Kuros Biosciences Ag Guanine-rich oligonucleotides
JPWO2017111137A1 (ja) 2015-12-22 2018-10-18 味の素株式会社 オリゴヌクレオチドの製造方法
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
US20190076814A1 (en) 2017-09-11 2019-03-14 Synthego Corporation Biopolymer synthesis system and method
CN111246936B (zh) * 2017-10-25 2022-05-03 深圳华大生命科学研究院 用于核酸合成的微流控芯片
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
KR102890791B1 (ko) 2018-04-09 2025-11-24 체크메이트 파마슈티칼스, 인크. 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
EP3850096A1 (en) * 2018-09-11 2021-07-21 Amgen Inc. Purification methods for guanine-rich oligonucleotides
WO2020090822A1 (ja) * 2018-10-30 2020-05-07 東レ株式会社 核酸の非特異結合抑制剤、ハイブリダイゼーション用試薬および核酸のハイブリダイゼーション方法
CN112969527A (zh) * 2018-11-08 2021-06-15 深圳华大生命科学研究院 一种微流控芯片及其制备方法和dna合成方法
EP4047004B1 (en) * 2019-10-18 2024-03-06 FUJIFILM Wako Pure Chemical Corporation Phosphoramidite activator
US20230322842A1 (en) * 2020-04-14 2023-10-12 Sumitomo Chemical Company, Limited Composition containing nucleic acid oligomer
CN114425443B (zh) * 2020-10-29 2025-10-31 江苏金斯瑞生物科技有限公司 一种寡核苷酸合成催化剂
GB202114688D0 (en) 2021-10-14 2021-12-01 Exactmer Ltd Solution phase polymer synthesis
GB202414228D0 (en) 2024-09-27 2024-11-13 Exactmer Ltd Solvent recycling in a liquid-phase process for preparing a defined monomoer sequence polymer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004749A1 (en) 1983-06-01 1984-12-06 Beckman Instruments Inc Novel preparation of nucleoside phosphoramidite intermediates
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
AU7350798A (en) 1997-04-29 1998-11-24 Universiteit Utrecht Corona virus-like particles as tools for vaccination and therapy
EP0980257A1 (en) 1997-05-01 2000-02-23 Chiron Corporation Use of virus-like particles as adjuvants
US6171591B1 (en) 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
US6541438B1 (en) 1998-05-01 2003-04-01 The Procter & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified cellulase
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
EP1165773A4 (en) 1999-02-02 2005-01-05 Biocache Pharmaceuticals Inc IMPROVED PLATFORM FOR PRESENTING ANTIGENS
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
SK287400B6 (sk) 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
EP1220684B2 (en) 1999-09-27 2010-07-14 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
DE60043708D1 (de) 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
ATE290399T1 (de) 1999-11-24 2005-03-15 Chiron Corp Hbv/hcv virus-ohnliche particle
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AU2001239873A1 (en) 2000-02-24 2001-09-03 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells
WO2002053141A2 (en) 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
US7524950B2 (en) * 2001-10-31 2009-04-28 Agilent Technologies, Inc. Uses of cationic salts for polynucleotide synthesis
CA2488856A1 (en) 2002-06-20 2003-12-31 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
US20060210588A1 (en) 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
EP1644034B1 (en) 2003-07-10 2011-01-12 Cytos Biotechnology AG Composition for enhancing an immune response comprising packaged virus-like particles
CA2544240A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
JP4628686B2 (ja) * 2004-02-25 2011-02-09 独立行政法人科学技術振興機構 ホスホロアミダイトを含む３’末端ヌクレオシドユニット
CN101076546B (zh) * 2004-09-02 2011-10-26 Isis药物公司 用于低聚物合成的聚合珠
CA2580208A1 (en) 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity

Also Published As

Publication number Publication date
CA2671873C (en) 2018-10-09
WO2008073960A3 (en) 2008-08-07
AU2007333147A1 (en) 2008-06-19
US9914746B2 (en) 2018-03-13
EP2125854B1 (en) 2016-10-26
US20160145293A1 (en) 2016-05-26
CN101611048A (zh) 2009-12-23
JP5389662B2 (ja) 2014-01-15
US20080139797A1 (en) 2008-06-12
US8586728B2 (en) 2013-11-19
US20140200338A1 (en) 2014-07-17
EP2125854A2 (en) 2009-12-02
WO2008073960A2 (en) 2008-06-19
JP2010512169A (ja) 2010-04-22
AU2007333147B2 (en) 2013-12-19
CA2671873A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
CN101611048B (zh) 含有高浓度鸟嘌呤单体的寡核苷酸
TWI738784B (zh) 製備寡聚物之方法
JP2021073204A (ja) グアニンリッチオリゴヌクレオチド
CN102076703B (zh) 用于制造寡核苷酸的方法
JP2024506135A (ja) オリゴヌクレオチドを脱トリチル化するための方法
KR20200035267A (ko) 이메텔스타트를 제조하기 위한 향상된 공정
AU2013204442A1 (en) Oligonucleotides Containing High Concentrations of Guanine Monomers
ES2741025T3 (es) Oligonucleótidos ricos en guanina
JP2000342265A (ja) オリゴヌクレオチド類の精製方法
EP4041741A1 (en) Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma
WO2023067038A1 (en) Process for oligonucleotide purification
WO2024053578A1 (ja) 核酸の製造方法、不純物の除去方法及び不純物が少ない核酸
HK40048836A (en) Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CYTOS BIOTECHNOLOGY AG

Free format text: FORMER OWNER: INTEGRATED DNA TECH INC.

Effective date: 20101227

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: ILLINOIS, USA TO: SCHLIEREN, SWITZERLAND

TA01 Transfer of patent application right

Effective date of registration: 20101227

Address after: Swiss Shi Lilun

Applicant after: CYTOS BIOTECHNOLOGY AG

Address before: Illinois, USA

Applicant before: INTEGRATED DNA TECHNOLOGIES, Inc.

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210917

Address after: Swiss Shi Lilun

Patentee after: Kuros Biosciences

Address before: Swiss Shi Lilun

Patentee before: CYTOS BIOTECHNOLOGY AG

Effective date of registration: 20210917

Address after: Delaware, USA

Patentee after: Kuros USA, LLC

Address before: Swiss Shi Lilun

Patentee before: Kuros Biosciences